Athenex Inc

Athenex — Investor Day (December 2018)

96 slides from Athenex's investor day presentation, Dec 17, 2018

  1. Slide 1: Athenex R&D Day December 17, 2018

    ATHENEX R&D Day December 17, 2018 CONFIDENTIAL Nasdaq: ATNX Exhibit 99.1

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements Except for historical information, all of the statements, expectations, and assumptions contained in this presentation constitute forward-looking statements. These statements include descriptions regarding the intent, belief or current expectations of Athenex, Inc. (the “C

  3. Slide 3: Agenda

    Introductions Corporate and R&D Overview Orascovery Platform + Q&A Src Kinase Inhibition Platform Break TCR-T Immunotherapy Platform Market and Collaborative Opportunity Oncology Innovation Platform Summary Business Model Closing + Q&A Agenda

  4. Slide 4: Presenters

    Johnson Lau, MBBS, MD, FRCP Chairman & Chief Executive Officer Rudolf Kwan, MBBS, MRCP Chief Medical Officer Simon Pedder, PhD Chief Business and Strategy Officer Timothy Cook Senior Vice President, Global Commercial Oncology David Cutler, MD, FRCPC Vice President, Clinical Development Jane Fang, MB

  5. Slide 5: Corporate and R&D Overview

    Johnson Lau Corporate and R&D Overview

  6. Slide 6: From R&D to Marketing – Value Chain

    Pharmaceutical/Biotechnology From R&D to Marketing – Value Chain Molecular Target Identification (Academics) R&D (Preclinical/Clinical) Athenex: Major Focus Marketing and Sales API/CMC Value Creation Focus: Oncology Synergy Team: Experience (Upstream and downstream integration) Understand the market

  7. Slide 7: Global Biotech Company Focused on Oncology

    Global Biotech Company Focused on Oncology 4 key technology platforms 8 US IND drug candidates 2 drug candidates in Phase 3 2 candidates advancing to Phase 2 Global Supply Chain Platform Commercial Platform Oncology Innovation Platform

  8. Slide 8: Key Technology Platforms

    Orascovery Oral chemotherapeutics using a novel, non-absorbed, selective P-gp inhibitor HM30181A Src Kinase Inhibition Novel small molecules with two MoAs: inhibition of Src Kinase inhibition of tubulin polymerization TCR-T Immunotherapy TCR-engineered T-cell therapy that enhances the patient’s own

  9. Slide 9: Transformative and Continually Expanding Pipeline

    Transformative and Continually Expanding Pipeline Program Drug Candidate Indication Pre-clinical Phase 1 Phase 2 Phase 3 Orascovery (P-gp + chemoRx agents) Oraxol (paclitaxel) Metastatic breast cancer Oraxol w/ ramucirumab Gastric cancer Oraxol w/ pembrolizumab Solid tumors Oraxol (paclitaxel) Angio

  10. Slide 10: Priming Biology of Cancer Treatment

    Priming Biology of Cancer Treatment Cancer Cell Growth / Metastasis TCR-T Recognize / Attack Conditioning Local Immune Stimulation Tumor Microenvironment Control/Maintenance Therapy

  11. Slide 11: Committed to Developing the Best Cancer Treatments

    Athenex is Committed to Developing the Best Cancer Treatments Oraxol Phase 3 topline data read-out Oratecan and Oradoxel advancing to Phase 2 Partnering for KX2-391 ointment in AK Expanding pipeline with new technologies and promising new drug candidates Marketing plans ready for two Phase 3 candida

  12. Slide 12: Orascovery Platform

    Rudolf Kwan David Cutler Douglas Kramer Orascovery Platform

  13. Slide 13: The Orascovery Platform

    The Orascovery Platform Chemotherapy Bioavailability Many chemotherapies have poor oral bioavailability due to active excretion by P-gp on intestinal cells Joo et al. Oncology Reports. 2008; 19:17-23 HM30181A Proprietary inhibitor of P-gp No significant inhibition to other transporters Oral Chemothe

  14. Slide 14: The Orascovery Platform: Pipeline

    Drug Candidate Chemotherapy Indication Pre-clinical Phase 1 Phase 2 Phase 3 Oraxol Paclitaxel Metastatic Breast Cancer Oraxol with ramucirumab Paclitaxel Gastric Cancer Oraxol with pembrolizumab Paclitaxel Solid Tumors Oraxol Paclitaxel Angiosarcoma Oratecan Irinotecan Solid Tumors Oradoxel Docetaxe

  15. Slide 15: The Orascovery Platform: Potential Indications

    ORAXOL Potential Strengths Development Potential indication Data Better efficacy Low neuropathy No infusion reaction PK PAC responsive CA AUC – can achieve IV level Mono MBC Ph 2 ORR > 45% Combo (Ramucirumab) 2nd line Gastric Ph 1b ORR = 50% Combo (Pembrolizumab) Urothelial; Gastric; NSCLC Orphan An

  16. Slide 16: Oraxol

    Oraxol| ;

  17. Slide 17: Bioavailability Study Comparing IV Paclitaxel and Oraxol

    Bioavailability Study Comparing IV Paclitaxel and Oraxol Abstract 2569 An open label, randomized cross-over bioavailability and extension study of Oral Paclitaxel and HM30181 (Oraxol) compared to weekly intravenous paclitaxel 80 mg/m2 in advanced solid tumours Christopher G. C. A. Jackson, Sanjeev D

  18. Slide 18: Summary PK Data and Results

    Paclitaxel (n=6) Mean (SD) Oraxol, Baseline (n=6) Mean (SD) Oraxol, Week 4 (n=10) Mean (SD) AUC0-∞, (hr*ng/mL) 5652 (1013) 5078 (1723) Cmax (ng/mL) 2269.44 (227.11) 230.99 (133.84) 238.8 (86.11) AUC0-56 2493.4 (731.96) 2615 (707.14) GMR (%, 90% CI) 87.09 (74.61-101.66) Intra-subject CV (%) 12.62 Pla

  19. Slide 19: Phase 2 Single-arm PK Study of Oraxol in MBC

    Phase 2 Single-arm PK Study of Oraxol in MBC Abstract 287PD An open label, single-arm pharmacokinetic study of oral paclitaxel and HM30181 in metastatic breast cancer patients Dai MS, Chao TY, Chao TC, Chiu CF, Lu YS, Shiah HS, Hung N, Fetterly G, Cutler DL, Kwan R, Kramer D, Chan W, Hung T Division

  20. Slide 20: Study Design

    Study Design Phase 2 single-arm PK study of Oraxol in MBC Multicenter, single-arm, open-label study in breast cancer patients 24 subjects evaluable for tumor response, recruited from six medical centers Endpoints PK at week 1 and week 4 Safety Activity – Tumor response rate Dosing 15 mg HM30181A plu

  21. Slide 21: Patient Characteristics

    Patient Characteristics Phase 2 single-arm PK study of Oraxol in MBC Age (years) 56.2±9.4 Metastasis No previous treatment 2 Bone 12 Previous treatment 22 Lungs 9 Endocrine therapy 20 Lymph nodes 9 Chemotherapy 20 Liver 9 Surgery 13 Right upper back 1 Radiation 11 Chest wall 1 Other 4 Pericardium 1

  22. Slide 22: Pharmacokinetic Results

    Pharmacokinetic Results Phase 2 single-arm PK study of Oraxol in MBC Dai et al. 2018 ESMO Congress. Munich Note: All data presented are interim data

  23. Slide 23: Tumor Response

    n=24 Tumor Response Phase 2 single-arm PK study of Oraxol in MBC *Patient had a new lesion Partial Response Stable Disease Progression-free after 16-weeks n (%) 11 (45.8) 10 (41.7) 21 (87.5) Dai et al. 2018 ESMO Congress. Munich Note: All data presented are interim data

  24. Slide 24: First-Line Monotherapy Regimens in Advanced Breast Cancer

    First-Line Monotherapy Regimens in Advanced Breast Cancer Sources: 1. O’Shaughnessy et al, 2001; 2. Spielman et al, 2001; 3. Fumoleau et al, 1993; 4. Jones et al, 2005; 5. Gradishar et al, 2006; 6. Roche et al, 2007; 7. McIntyre et al 2014 Regimen No. Patients RR (%) TTP (months) OS (months) Capecit

  25. Slide 25: Conclusions

    Conclusions Phase 2 single-arm PK study of Oraxol in MBC Plasma paclitaxel exposure (AUC) of oral paclitaxel achieved is similar to that reported for weekly IV paclitaxel The tumor response rate (PR= 45.8%, SD= 41.7%) of Oraxol in treatment of breast cancer patients who failed previous chemotherapie

  26. Slide 26: Phase 3 Study of Oraxol Compared to Taxol in MBC

    Phase 3 Study Of Oraxol Compared To Taxol In Metastatic Breast Cancer KX-ORAX-001

  27. Slide 27: KX-ORAX-001: Study Design and Objectives

    KX-ORAX-001: Study Design and Objectives Oraxol Phase 3 study in metastatic breast cancer An open-label, randomized, multicenter Phase 3 study to determine the safety, tolerability, and tumor response of Oraxol compared with IV paclitaxel in subjects with metastatic breast cancer n = 360 Oraxol 2:1

  28. Slide 28: KX-ORAX-001: Current Enrollment Status

    KX-ORAX-001: Current Enrollment Status Eligibility criteria Adult female with histologically- and cytologically-confirmed metastatic breast cancer for whom treatment with IV paclitaxel monotherapy has been recommended by their oncologist Must have measurable metastatic target lesion disease as per R

  29. Slide 29: 2nd Interim Analysis

    2nd Interim Analysis DSMB Futility: Oraxol group has <10% higher confirmed response rate than IV paclitaxel Success: Oraxol demonstrates higher confirmed response rate than IV paclitaxel (p<0.004) Otherwise, the study will continue enrolling a total of 360 evaluable for the final analysis Study cont

  30. Slide 30: Oraxol-plus-Ramucirumab Study in Gastric Cancer

    Oraxol-plus-Ramucirumab Study in Gastric Cancer Phase 1b In collaboration with Eli Lilly Study conducted in Taiwan/USA Safety profile: Dose limiting dose not yet reached Oraxol Dose (mg/m2) Partial Response Rate First cohort 200 2 / 6 Second cohort 250 3 / 6 Third cohort 300 Ongoing Note: In the Pha

  31. Slide 31: Oraxol Regulatory Roadmap

    Oraxol Regulatory Roadmap Phase 3 primary data read-out Mid 2019 NDA submission Approval Depends on FDA review time Additional Indications Gastric cancer Angiosarcoma (Orphan drug designation) Combo with Anti-PD1 and Anti-PD-L1 USA EU – MHRA China Global Strategy

  32. Slide 32: Oratecan and Oradoxel

    Oratecan Oradoxel 4 » ee _

  33. Slide 33: Oratecan (HM30181A + Oral Irinotecan)

    MTD study Single dose of oral irinotecan + HM30181A once per 21 day cycle Dose range: 20 to 320 mg/m2 Oratecan (HM30181A + Oral Irinotecan) Oratecan dose ranging: ORTE-01-14 US Irinotecan is indicated in the treatment of colorectal cancer Following IV administration it is converted to SN38, an activ

  34. Slide 34: Oratecan Plasma Pharmacokinetics: AUC24 Comparison

    IRINOTECAN SN38 Oratecan Plasma Pharmacokinetics: AUC24 Comparison Reference lines values for 125 mg/m2 were obtained from the Camptosar Label A single dose administration of Oratecan at 200 mg/m2 or above can achieve SN38 exposures (AUC24) comparable to those in the Camptosar label Dose (mg/m2) Dos

  35. Slide 35: Oradoxel (HM30181A + Oral Docetaxel)

    Oradoxel (HM30181A + Oral Docetaxel) Oradoxel clinical studies KX-ORADOX-002 Single dose PK crossover bioavailability study IV docetaxel at prescribed dose Oradoxel 75, 150 or 225 mg/m2 KX-ORADOX-003 MTD study of Oradoxel q 3 weeks Doses 35, 75, 150, 225 mg/m2 IV docetaxel is indicated for use in br

  36. Slide 36: Oral Docetaxel PK Summary

    Oral Docetaxel PK Summary KX-ORADOX-002 and KX-ORADOX-003 Note: All data presented are interim data

  37. Slide 37: Summary of Docetaxel Pharmacokinetic Parameters

    Summary of Docetaxel of Pharmacokinetic Parameters Docetaxel pharmacokinetics are increasing with dose AUC was calculated using the log-linear trapezoidal rule Values in table are Mean (CV%) Study Route Dose (mg/m2) Cmax (ng/mL) AUC0-inf (ng.hr/mL) KX-ORADOX-002 (NZ) IV 60 N=3 1310 (21.1%) 1920 (13.

  38. Slide 38: Oratecan and Oradoxel: Summary

    Oratecan and Oradoxel: Summary Accumulating PK data indicates that docetaxel exposure increases with dose and that exposure similar to that achieved with IV dosing is feasible with 1 or 2 days of dosing every 3 weeks Phase 2 studies are being planned in HPRC, NSCLC Oratecan A recommended Phase 2 dos

  39. Slide 39: Q&A

    Q&A

  40. Slide 40: Src Kinase Inhibition Platform

    Rudolf Kwan Simon Pedder Jane Fang Src Kinase Inhibition Platform

  41. Slide 41: Actinic Keratosis (AK)

    Actinic Keratosis (AK) Actinic Keratosis Sources: EvaluatePharma Sources: Fuchs A, Marmur E. The kinetics of skin cancer: progression of actinic keratosis to squamous cell carcinoma. Dermatol Surg. 2007 33(9):1099-101 Sources: Frost CA, et al. British Journal of Dermatology. 1994;131(4):455-464 Unit

  42. Slide 42: Almirall and Athenex Collaboration

    For AK Leadership Almirall and Athenex Collaboration and Additional Opportunities Almirall: ACTINIC KERATOSIS Recognized as the leader in the field of AK treatment Believes that KX2-391 will become the new standard-of-care for AK globally GLOBAL OPPORTUNITIES FOR KX2-391 Continue to discuss with pot

  43. Slide 43: Almirall and Athenex Collaboration: Deal Economics

    Almirall and Athenex Collaboration: Deal Economics Upfront / Near Term Payments Up to US$ 55 million Recognized US$ 30 million in 2018 Launch and additional indications milestones: US$ 65 million Sales performance milestones: US$ 155 million (estimated) + additional milestones with higher sales Tier

  44. Slide 44: Limitations of Current Therapies

    Barriers to effective AK treatment include1: Poor disease awareness (for both patient and physician) Concerns associated with the cosmetic effects of treatment Treatment-related side effects Inadequate adherence, particularly with long treatment duration 1. E. Stockfleth et al. J Eur Acad Dermatol V

  45. Slide 45: Local Skin Reactions with Picato

    Local Skin Reactions (LSR) Experienced by Patients Using Picato® (ingenol mebutate) DOSING REGIMEN Once daily for 3 consecutive days Source: http://picato.com/what-to-expect 0.015% Mild Moderate Severe

  46. Slide 46: Phase 3 Pivotal Studies in AK

    Two identical studies: KX01-AK-003 and KX01-AK-004 351 subjects enrolled in 31 US sites per study (total 702 subjects in 62 sites) Face to Scalp 2:1 KX2-391 Ointment 1% to Vehicle 1:1 Treatment: Daily for 5 consecutive days Treatment area: 25 cm2 with clinically typical visible 4-8 AK lesions on fac

  47. Slide 47: Phase 3 Pivotal Studies in AK: Key Findings

    Phase 3 Pivotal Studies in AK: Key Findings Up to Day 57 Achieved primary endpoint: Significantly higher % of subjects on KX2-391 ointment 1% than those on vehicle achieving 100% clearance of AK lesions at Day 57 within the face or scalp treatment areas (p<0.0001 per study) Statistical significance

  48. Slide 48: Phase 2 Modified Dose Regimen-Finding Study

    Phase 2 Modified Dose Regimen-Finding Study Open-Label, Multicenter, Activity and Safety Study of KX2-391 Ointment 1% in Subjects AK on the Face or Scalp Sites 16 US sites Study Drug KX2-391 Ointment 1% Two cohorts Cohort 1: Daily for 5 consecutive days, N=84 Cohort 2: Daily for 3 consecutive days,

  49. Slide 49: Clearance of AK at Day 57

    Cohort Clearance of AK at Day 57 Responders/ Total Number (%) Face Scalp Overall 5-Day 100% 23/44 (52%) 13/40 (33%) 36/84 (43%) ≥75% 29/44 (66%) 18/40 (45%) 47/84 (56%) 3-Day 100% 20/66 (30%) 7/18 (39%) 27/84 (32%) ≥75% 35/66 (53%) 9/18 (50%) 44/84 (52%) Activity of KX2-391 in Field Treatment of Act

  50. Slide 50: KX2-391 Well Tolerated with Mostly Mild Local Reactions

    Photos of the subject with score 4 for erythema and flaking/scaling Day 1, Pre-treatment Day 8 Day 57 Phase 2 modified dose regimen-finding study KX2-391 was Well Tolerated and Resulted in Mostly Mild Local Reactions Oral presentation at AAD 2018

  51. Slide 51: Incidence of Post-Baseline Maximal LSR Score

    Incidence of Post-Baseline Maximal LSR Score Vesicles/ Pustules Erosions/ Ulcers Swelling Crusting Flaking/ Scaling Erythema 5-Day 3-Day 5-Day 3-Day 5-Day 3-Day 5-Day 3-Day 5-Day 3-Day 5-Day 3-Day 0 80 (95%) 83 (99%) 71 (85%) 79 (94%) 66 (79%) 76 (90%) 51 (61%) 58 (69%) 33 (39%) 39 (46%) 15 (18%) 30

  52. Slide 52: KX2-391 Ointment Regulatory Roadmap

    KX2-391 Ointment Regulatory Roadmap Program led by Athenex Phase 3 follow-up data expected in Q2 2019 NDA submission to be followed when CSR and toxicology package are available Variables in the FDA review time (pre-NDA meeting with FDA planned) Program led by Almirall Will leverage the US data Exte

  53. Slide 53: Src Kinase Inhibition Platform: KX2-361 (KX-02)

    Src Kinase Inhibition Platform: KX2-361 (KX-02) Phase 1 candidate for GBM Crosses blood-brain-barrier Stimulates the immune system to inhibit future tumor growth Cleared tumors pre-clinically Development: Phase 1 in the U.S. China FDA Phase 1 expected in Q4’18 Orphan drug designation for GBM Mouse G

  54. Slide 54: Break

    Break

  55. Slide 55: TCR-T Immunotherapy Platform

    Johnson Lau TCR-T Immunotherapy Platform

  56. Slide 56: TCR Affinity Enhanced Specific T-cells (TAEST)

    TCR Affinity Enhanced Specific T-cells (TAEST) Patients T cells engineered to express a High Affinity TCR (HAT) that directs tumor specific cytotoxicity Release of Cytokines and Lytic Granules High Affinity TCR (HAT) redirected cytotoxic T cells (CTL) Target cell T-cell T-cell Peptide MHC complexes

  57. Slide 57: Advantages of TAEST

    Advantages of TAEST CD8 Low Low High HAT High CD8+ Cytotoxic T cells expressing HAT ~86% of cells express HAT Binding Affinity: Kd 1.5 uM vs 43 uM (wild type) Advantages: 1. Activity (even with low peptide/MHC expression) 2. Not too “sticky” – less off-target activity No activity against antigen neg

  58. Slide 58: Advantages of TAEST (Con't)

    Advantages of TAEST (Con’t) 01 Higher Binding Affinity of Engineered TCR 06 Persistence of TCR-T In Vivo in Some Patients 04 Good Anti-tumor Activity (In Vivo) 05 Broad Patient Coverage Lung cancer Sarcoma Current HATs being developed for patients expressing HLA A0201, A1101, or A2402 > 90% coverage

  59. Slide 59: TAEST Phase 1 Study – First Stage

    Objectives: Safety of TCR-T alone (dose escalation and without lymphodepletion) Cancer antigen target – NY-ESO-1 in the context of HLA-A0201 Three patients (failed all previously available treatment): TAEST Phase 1 Study – First Stage Patient ID Gender / Age Tumor Type NY-ESO-1 + (%) Total Cell No.

  60. Slide 60: Cytokine Response and TCR-T Persistence

    TCR-T Persistence Cytokine Responses Phase 1 (First Stage): Cytokine Response and TCR-T Persistence Pre-Rx Pre-Rx Pre-Rx Pre-Rx Pre-Rx Pre-Rx #1 (GYYY-001-QYF) 3rd infusion #2 (GYYY-002-WXL) #3 (GYYY-003-XLF) #1 (GYYY-001-QYF) 3rd infusion #2 (GYYY-002-WXL) #3 (GYYY-003-XLF)

  61. Slide 61: Phase 1 Pilot Study (with Lymphodepletion Protocol)

    Patient ID Gender/ Age Tumor Type NY-ESO-1 + (staining intensity, %) Total Cell No. Infused Efficacy #4 GAS F/53 NSCLC ++ 90% 2.69×10^10 cells SD for 8 weeks #5 XCC M/47 Thyroid cancer + 25% 1.68×10^10 cells SD for 12 weeks (with significant tumor necrosis) #6 LLM F/49 Synovial sarcoma +++ 70% 1.67×

  62. Slide 62: Phase 1 Pilot Study: Adverse Events

    Phase 1 Pilot Study: Adverse Events AE (Grades from 0-4) NSCLC Synovial Sarcoma Thyroid Cancer Liver Cancer Breast Cancer No of AE cases AE rate GAS GZY LLM XCC XJY FYH Fever 3 3 3 2 4 4/6 Chills 1 1 1 1 5 5/6 Low blood pressure 2 3 2 2/6 Peripheral edema 1 3 2 2/6 Neutropenia 4 3 2 2 3 3 6 6/6 Thro

  63. Slide 63: Two Patients with Partial Responses

    Two Patients with Partial Responses Biomarker Day 0 Day 14 CEA 2162 953 CA125 5944 1865 CYFRA21-1 274.8 86.3 NSE 38.4 13.4 #6 LLM – Synovial Sarcoma – Target tumor in the lung Day 0 Day 60 #8 FYH – Breast Cancer – Target tumor (metastatic tumor, lung) Day 0 Day 28

  64. Slide 64: Skin ulcer healing post-TCR-T

    Skin ulcer healing post-TCR-T Day 0 Day 28 Patient #8 FYH Both cancer skin ulcers healed post TCRT therapy One ulcer did recur later - confirming the malignant nature of the cancer ulcer #8 FYH – End-stage Breast Cancer Patient had two cancer skin ulcers Both cancer skin ulcers healed post TCR-T the

  65. Slide 65: Tumor Necrosis of Target Metastasis Observed in Two Patients

    #5 XCC – Thyroid Cancer Target metastatic tumor in neck (note the tumor necrosis with vacuolation): Size -13% Day 0 Day 14 #7 XJY – Liver Cancer Retroperitoneal metastatic recurrence after primary cancer removal – target tumor (note the tumor necrosis with vacuolation): Size +1% Day 0 Day 14 Tumor N

  66. Slide 66: Phase 1 Pilot Study: Cytokine Release Observed in All Patients

    Phase 1 Pilot Study: Cytokine Release Observed in All 6 Patients Pre-Rx Pre-Rx Pre-Rx Pre-Rx Pre-Rx Pre-Rx

  67. Slide 67: Duration of TCR-T Detected in the Circulation

    Pre-Rx Phase 1 Pilot Study: Duration of TCR-T Detected in the Circulation Pre-Rx Pre-Rx Pre-Rx Pre-Rx Pre-Rx

  68. Slide 68: Axis Therapeutics Highlights

    Axis Therapeutics Highlights TCR-T based Cancer Immunotherapy Platform Acceptable safety profile Efficacy demonstrated in some patients First 6 patients: 2 PR, 4 SD (with two showing significant tumor necrosis) Evidence for TCR-T cell persistence in some patients Phase 1 Study (preliminary results)

  69. Slide 69: Market and Collaborative Opportunity

    Timothy Cook Simon Pedder Market and Collaborative Opportunity

  70. Slide 70: US Expected to Remain Largest and Fastest Growing Oncology Market

    US Expected to Remain Largest and Fastest Growing Oncology Market Therapeutic and Supportive Care $96bn $133bn $193bn 49.2%* 46.6%* 40.6%* Sources: IQVIA MIDAS, IQVIA Institute, Dec 2017, Global Oncology Trends 2018. IQVIA Institute The forecast figures and/or estimates are not guarantees of future

  71. Slide 71: Orascovery Platform Covers a Large Majority of Common Cancers

    Orascovery Platform Covers a Large Majority of Common Cancers A GLOBOCAN 2018 projected mortality B At least one portfolio product having a FDA indication C At least one portfolio product having an NCCN listing. Represents non-promoted use. Covered Uses USA WWA % indicated cancersB 64% 61% % NCCN li

  72. Slide 72: Defining the Opportunity in Metastatic Breast Cancer

    Breast Cancer: Total Lifetime Prevalence: 3,418,1241 Breast Cancer: Diagnosis 0 to < 5 year Prevalence: 1,000,6411 Stage I-III (~ 85-95%)2 Metastatic Breast Cancer (~ 5-15 %)2 Focus: Curative care for all tumor types Focus: Palliative care for all tumor types Surgery HER2+ ~ 13% HR+/HER2- ~ 64% TNBC

  73. Slide 73: Consensus Forecast for Taxane Market By 2024

    Consensus Forecast Indicates that Oral Paclitaxel & HM30181A Will Drive Significant Growth in the Taxane Market By 2024 Source: Evaluate Pharma Ltd 2018 The forecast figures and/or estimates are not guarantees of future performance and involve risks and uncertainties. Actual results might differ mat

  74. Slide 74: Oral Paclitaxel Opportunity

    FDA approvals: Breast, NSCL, Ovarian, Pancreas Major NCCN: Bladder, H&N, Esophagus Over 2.7 millionA doses per year in the US, ~2.0 million excluding adjuvant breast cancer Significant opportunity to combine with other products Oral Paclitaxel Opportunity A IntrinsiQ Nov17-Oct18, paclitaxel and nab-

  75. Slide 75: Oral Docetaxel Opportunity

    FDA approvals: Breast, NSCL, Prostate, Stomach, H&N Major NCCN: Pancreas, Bladder, Esophagus, Ovary Over 1.2 millionA doses per year in the US Oral Docetaxel Opportunity A IntrinsiQ Nov17-Oct18, docetaxel B WW opportunity scaled from US opportunity (US=60% of WW opportunity) FDA=Food and Drug Admini

  76. Slide 76: Oral Irinotecan Opportunity

    FDA approvals: Colon, Rectal Major NCCN: Pancreas, Brain, Esophagus, Stomach, Small Cell Lung (SCLC) Over 0.9 millionA doses per year in the US Oral Irinotecan Opportunity A IntrinsiQ Nov17-Oct18, irinotecan and liposomal irinotecan B WW opportunity scaled from US opportunity (US=60% of WW opportuni

  77. Slide 77: Src Kinase Glioblastoma Opportunity

    FDA approved drugs: temozolomide, bevaciziumab Brain Cancer MortalityA: 16,902 US and 203,196 WW Glioblastoma accounts for 52% of brain cancers Src Kinase Glioblastoma Opportunity A GLOBOCAN 2015 estimates B WW opportunity scaled from US opportunity (US=60% of WW opportunity) FDA=Food and Drug Admin

  78. Slide 78: TCR-T Opportunity

    TCR-T Opportunity Cancer Type US MortalityB NY-ESO-1 PRAME RHAMM AFP Lung 152,423 18-25% (NSCLC) 46-78% Breast 41, 904 17% (TNB) 27-53% 55-76% Liver 30,485 15-43% 72% 60-80% Prostate 28,705 5-30% 46% (CRPC) Leukemia 23,882 30-64% (AML) 28% (AML) Ovarian 14,008 43% 60% Melanoma 9,491 20-28% (metastat

  79. Slide 79: Worldwide AK Treatment Market

    Worldwide AK Treatment Market Growing awareness of AK and the need for treatment Annual visits to dermatologists for AK – current: 5.2M2 Potential to displace non-topical treatments % of AK patients using topical – current: est. > 50% Potential for KX2-391 to be the standard-of-care for treatment fo

  80. Slide 80: Total Portfolio Potential

    Total Portfolio Potential Note: Chart figures do not include estimate of KX2-391 opportunity The forecast figures and/or estimates are not guarantees of future performance and involve risks and uncertainties. Actual results might differ materially from the forecast figures and/or estimates. Summary

  81. Slide 81: Orascovery Combination Opportunities

    Orascovery Combination Opportunities Drug Mechanism Company Indication Ramucirumab (Cyramza™) Anti-VEGFR2 IgG1 Eli Lilly Advanced gastric cancer Pembrolizumab (Keytruda®) Anti-PD-1 IgG4 Merck Gastric, urothelial, lung cancers Bevacizumab (Avastin®) Anti-VEGF IgG1 Genentech (Roche) Metastatic breast

  82. Slide 82: Oraxol Enables All-Oral Combination Therapies

    Oraxol Enables All-Oral Combination Therapies Drug Mechanism Company Indication Rationale Ipatasertib AKT inhibitor Roche Metastatic triple-negative breast cancer AKT activation in TNBC Taxanes sensitize cells to AKT pathway inhibition Phase 2 data; Phase 3 ongoing Vandetanib (Caprelsa®) VEGFR, EGFR

  83. Slide 83: Oraxol Business Development Activities

    Oraxol Business Development Activities Continue to explore with potential partners Big Pharma awaiting Phase 3 data Position Oraxol (Orascovery) as a new standard for Chemotherapy Concentrating on EU/Japan global players For those companies, the US not a “must have” Will continue discussion with US

  84. Slide 84: Oncology Innovation Platform Summary

    Michael Smolinski Teresa Bair Johnson Lau Oncology Innovation Platform Summary

  85. Slide 85: Next Generation Oral Absorption Enhancer NACP

    Next Generation Oral Absorption Enhancer “NACP” – Non-Absorbable Cyp and P-gp Inhibitor Inhibition of intestinal Cyp and P-gp can provide added oral bioavailability enhancement over P-gp inhibition alone New chemical entity and potential for more applications

  86. Slide 86: Pegylated, Genetically Modified Human Arginase

    Pegylated, Genetically Modified Human Arginase Biological Therapeutic Depriving Cancers of a Key Resource for Proliferation Arginine depletion for ASS1/OTC deficient cancers An essential amino acid for cancer growth and survival Many tumors are deficient in ASS and/or OTC hence dependent on external

  87. Slide 87: Potential Indications for Pegtomarginase

    Potential Indications for Pegtomarginase *Adapted from Biomedicine & Pharmacotherapy 102 (2018) 594–601 ASS1 deficiency is significant in cancers of high incidence and of significant medical need Many opportunities for combination with other Athenex pipeline therapeutics Summary of ASS1 expression i

  88. Slide 88: Competitive Landscape for Pegtomarginase

    Competitive Landscape for Pegtomarginase Pegtomarginase has the optimal product profile US FDA IND application expected 1H2019 Therapeutic Company PEG modality Catalytic efficiency Enzyme source Development stage PEGylated ADI Polaris Pharma Multiple and random High Mycoplasma (immunogenic) Phase 3

  89. Slide 89: Athenex Patent Portfolio

    Athenex Patent Portfolio Overall Portfolio Athenex owns over 100 granted patents across the pipeline, plus over 40 pending patent applications worldwide Oraxol We have in-licensed composition of matter patents from Hanmi Pharmaceuticals US, Europe, China and other countries Expiry: October 2024, exc

  90. Slide 90: Business Model

    Johnson Lau Business Model

  91. Slide 91: From R&D to Marketing – Value Chain

    Pharmaceutical/Biotechnology Molecular Target Identification (Academics) R&D (Preclinical/Clinical) Athenex: Major Focus Marketing and Sales API/CMC From R&D to Marketing – Value Chain Value Creation Focus: Oncology Synergy Team: Experience (Upstream and downstream integration) Understand the market

  92. Slide 92: From R&D to Marketing – Value Chain (Con't)

    Pharmaceutical/Biotechnology Acquired in 2015 Acquired in 2014 Public-private partnerships in 2015 API manufacturing Oncology drug pilot plant (for development stage) Oncology drug manufacturing facility (for commercialization stage) Polymed & Taihao (Chongqing, China) Athenex Pharma Solutions (Clar

  93. Slide 93: Closing

    Johnson Lau Closing

  94. Slide 94: Summary

    Summary The forecast figures and/or estimates are not guarantees of future performance and involve risks and uncertainties. Actual results might differ materially from the forecast figures and/or estimates. Two more promising products to come soon 8 Active Clinical Products in Development Oraxol and

  95. Slide 95: Management Team with Deep Pharma/Biotech Experience

    Johnson Lau MBBS, MD, FRCP Chief Executive Officer, Chairman 25+ years experience Jeff Yordon Chief Operating Officer 45+ years experience Rudolf Kwan MBBS, MRCP Chief Medical Officer 30+ years experience Simon Pedder PhD Chief Business & Strategy Officer 25+ years experience Timothy Cook Senior Vic

  96. Slide 96: Thank you

    Q&A Thank you fo r

Athenex — Investor Day (December 2018) on 6ix